Time delay toxin activation
{{Short description|National Library Kolkata}}{{no footnotes|date=June 2015}}
Time Delay Toxin Activation (TDTA) belongs to a class of chemotherapy drugs known as High Specificity Anticancer Agents. This is a process for manufacturing and administering chemotherapy drugs in a nontoxic, proto-drug form. Then, after a time delay to allow for concentration in the target cancer or invasive tissues or cells, the non-toxic drug is then modified by an activation drug to selectively provide toxic levels of a pharmacologically active agent to the target issue. This minimizes the toxicity to healthy cells, reducing the adverse side-effects of chemotherapy.
This idea was first proposed by Dr. Evan Harris Walker in 1980.
References
- {{cite web
| title = US Patent Office application number 20040192578
|url=http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040192578%22.PGNR.&OS=DN/20040192578&RS=DN/20040192578
| accessdate = February 2, 2006
}}
- {{cite web
|title=High specificity anticancer agents
|work=USPTO Full text patent database
|url=http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=/netahtml/search-bool.html&r=1&f=G&l=50&co1=AND&d=ptxt&s1=6,767,919.WKU.&OS=PN/6,767,919&RS=PN/6,767,919
|accessdate=January 29, 2006
}}
{{DEFAULTSORT:Time Delay Toxin Activation}}
{{oncology-stub}}